Trivium Point Advisory LLC Takes Position in Guardant Health, Inc. $GH

Trivium Point Advisory LLC purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,457 shares of the company’s stock, valued at approximately $819,000.

Other hedge funds have also recently added to or reduced their stakes in the company. World Investment Advisors acquired a new position in shares of Guardant Health during the 4th quarter worth $1,664,000. Orbimed Advisors LLC acquired a new stake in shares of Guardant Health in the 1st quarter valued at $40,199,000. Caxton Associates LLP acquired a new stake in shares of Guardant Health in the 1st quarter valued at $831,000. Styrax Capital LP boosted its holdings in Guardant Health by 6.5% in the first quarter. Styrax Capital LP now owns 300,000 shares of the company’s stock worth $27,711,000 after purchasing an additional 18,411 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its holdings in Guardant Health by 218.1% in the first quarter. Quantinno Capital Management LP now owns 16,831 shares of the company’s stock worth $1,555,000 after purchasing an additional 11,540 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling

In related news, Director Medina Manuel Hidalgo sold 1,700 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $164.24, for a total transaction of $279,208.00. Following the completion of the sale, the director owned 4,556 shares in the company, valued at $748,277.44. This represents a 27.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ian T. Clark sold 14,180 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the completion of the sale, the director directly owned 2,975 shares in the company, valued at $472,787. This trade represents a 82.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 784,234 shares of company stock valued at $106,493,352 in the last quarter. Insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

Guardant Health stock opened at $157.21 on Monday. The firm has a market cap of $21.10 billion, a price-to-earnings ratio of -45.05 and a beta of 1.60. Guardant Health, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $176.58. The firm has a fifty day moving average price of $150.40 and a two-hundred day moving average price of $116.89.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. BTIG Research raised their target price on Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a report on Friday, July 31st. Guggenheim increased their price objective on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Evercore reissued an “outperform” rating and set a $200.00 price objective on shares of Guardant Health in a report on Monday, July 6th. UBS Group set a $150.00 price objective on Guardant Health in a research note on Wednesday, June 24th. Finally, JPMorgan Chase & Co. boosted their target price on Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.